CPP 103: ICI PROSTATE CANCER PRECEPTORSHIP 

Multidisciplinary management, standards of care, optimal diagnostics, therapies and future perspectives in the care of Prostate Cancer patients in sub-Saharan Africa. 

Eldoret, Kenya 

Training Dates: 11th October 2022 – 16th November 2022 

Training Duration: 6 weeks 

Course Director: Prof. Fredrick Chite Asirwa MD 

Consultant Physician. Medical Oncologist & Hematologist 

Executive Director/CEO: International Cancer Institute (ICI) 

P.O. Box 8088, Code 30100 Eldoret, Kenya 

Email: director@intercancer.com Website: www.intercancer.com 

Lead Course Faculty: 

Dr. Kevin Makori MD, MMED 

Clinical & Radiation Oncologist 

Deputy Director of Programs 

International Cancer Institute (ICI) 

P.O. Box 8088, Code 30100 Eldoret, Kenya 

Email: kevin.makori@intercancer.com Website: www.intercancer.com 

This educational activity is provided independently by International Cancer Institute (ICI) Through the Blueprint Program 

Accreditation of this course is by KMPDC, PPB, NCK, and COC

Target Audience 

The primary target audience for this course comprises the multidisciplinary clinical cancer care team members including, but not limited to medical, surgical, and radiation oncologists; urologists; other health care professionals (internists, primary care physicians, pathologists, physicians-in-training, urology nurses, oncology nurses, nurse practitioners, pharmacists, physician assistants and nurse practitioners) involved and/or interested in the therapeutic management of patients with prostate cancer. 

LEARNING OBJECTIVES 

At the end of this educational activity, participants should be able to: 

1. Understand the Epidemiology of Prostate Cancer (Global) 
2. To understand the role of screening for prostate cancer, including the evidence for and against the use of prostate-specific antigen (PSA) screening and the practical indications of serum PSA measurement in different clinical settings 
3. recognize the role of pathological diagnosis, histologic grading, Gleason system, staging, and prognostic factors in prostate cancer. 
4. To understand the role of Surgery in the management of localized prostate cancer 5. To understand the role of radiotherapy in the management of localized prostate cancer 6. understand the management options for hormone-sensitive metastatic prostate cancer 
5. To understand the definition of castration-resistant prostate cancer (CRPC) and appreciate the novel therapies, their use, and their side effects profile in m-CRPC. 
6. Discuss treatment options for patients with advanced prostate cancer, including secondary hormonal therapy, chemotherapy, immunotherapy, and radioisotope therapy 
7. Understanding how and when to use bone-targeted therapies and the prevention and treatment of osteonecrosis of the jaw 
8. To understand the role of the multidisciplinary team in prostate cancer management 11. To understand the role of Palliative, supportive, and survivorship care in prostate cancermanagement 
9. Ability to diagnose and manage spinal cord compression, one of the most devastating complications of metastatic prostate cancer 
10. To discuss clinical cases between faculty and participants 

Disclosure of Conflicts of Interest 

International Cancer Institute (ICI) requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by ICI for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. The faculty must report any financial relationships or contractual relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity. Disclaimer 

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Disclosure of Unlabeled Use 

This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Method of Participation and Request for Credit 

To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures, and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately.

The Program 

LECTURES 

1. Orientation to the course (Chite) Tuesday, 11th October 2022 3:00 – 4:00 PM EAT 2. Epidemiology of Prostate cancer (Achille) Tuesday, 11th October 2022 4:00 – 5:30 PM EAT 
2. Screening and diagnostic workup for prostate cancer (Sitna) Wednesday, 12th October 2022 4:00-5:30PM EAT 
3. Role of Pathology in prostate cancer management (Kibet) Monday, 17th October 2022 4:00-5:30 PMEAT 
4. Pharmacology of systemic therapies in Prostate Cancer (Weru) Wednesday, 19th October 20224:00-5:30 PM EAT 
5. Role of Surgery in the management of localized prostate cancer (Dinesh/Urologist) Monday, 24th October 2 0 2 2 4:00-5:30 PM EAT 
6. Role of radiotherapy in the management of localized prostate cancer (Verna) Wednesday, 26th October 2 0 2 2 4:00-5:30 PM EAT 
7. Management of hormone-sensitive metastatic prostate cancer and use of bone-targeted therapies (Yesufe) Monday, 31st October 2022 4:00-5:30 PM EAT 
8. Treatment options for advanced prostate cancer, including chemotherapy, immunotherapy, and radioisotope therapy (Achille) Wednesday, 2nd November 2022 4:00-5:30 PM EAT 10. Diagnosis and management of spinal cord compression in prostate cancer patients (Helena) Monday, 7th November 2022 4:00-5:30 PM EAT 
9. Novel therapies, their use and side effects profile in metastatic castrate-resistant prostate cancer (Makori) Wednesday, 9th November 2022 4:00-5:30 PM EAT 
10. Supportive, Palliative, and Survivorship care in Prostate Cancer Care (Zippy) Monday, 14th November 2 0 2 2 4:00 – 4:30 PM 
11. Expert Panel Case discussions in prostate cancer management (Chite & Expert Panelists) Wednesday, 16th November 2022 4:00-5:30 PM EAT 
12. End of course examination (Education office) Friday, 18th November 2022 4:00-5:30 PM EAT CPP 103: ICI Prostate Cancer Preceptorship Course Schedule 

Participants should be willing to spend at least 4 hours per week on this online course over a period of 6 weeks. (Duration 24 hours). This program will start when the class is fully subscribed. The course Cost is $200.00 for the entire course. There are few sponsorships available on a first-come basis for those who apply. Priority will be given to those working in cancer centers that have formal affiliations/Partnerships with the International Cancer Institute. Apply for sponsorship during the registration of the course 

All those interested in registering for this course, please register your information on www.elearning.intercancer.com if you have any questions or queries please send an email to education@intercancer.com or director@intercancer.com 

For more information visit our website www.intercancer.com 

International Cancer Institute (ICI) ©2022 

Your Partner in Cancer Control in SSA